US · SLDB · BIOTECHNOLOGY
Solid Biosciences Inc. (SLDB) intrinsic value and stock valuation
$6.25as of 2026-11-21 · Mkt cap 825.99M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Solid Biosciences Inc. DCF and intrinsic value
InvestorsCraft values SLDB with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from SLDB’s statements →
Solid Biosciences Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2015–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- LB Pharmaceuticals Inc Common Stock (LBRX) $38.85
- Annexon, Inc. (ANNX) $3.10
- Design Therapeutics, Inc. (DSGN) $9.02
- Autolus Therapeutics plc (AUTL) $0.91
- Aura Biosciences, Inc. (AURA) $6.87
- Benitec Biopharma Inc. (BNTC) $7.92
- Rocket Pharmaceuticals, Inc. (RCKT) $1.95
- Neumora Therapeutics, Inc. Common Stock (NMRA) $0.33
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $8.09M | $13.6M |
| Operating income | -$-179.21M | -$-129.73M | -$-104.31M | -$-106.45M | -$-72.25M |
| Net income | -$-174.32M | -$-124.7M | -$-96.02M | -$-85.98M | -$-72.19M |
| EPSd | -$-1.99M | -$-3.05M | -$-4.83M | -$-10.1M | -$-10.14M |
| Operating cash flow | -$-156.29M | -$-100.01M | -$-94.18M | -$-97.98M | -$-77.76M |
| Capital expenditure | -$-1.15M | -$-650K | -$-1.51M | -$-3.02M | -$-1.28M |
| Free cash flow | -$-157.44M | -$-100.67M | -$-95.69M | -$-100.99M | -$-79.05M |
| Total assets | $232.5M | $188.7M | $164.9M | $260.3M | $232.4M |
| Total debt | $21.2M | $24.2M | $26.3M | $28.6M | $2.06M |
| Net debt | -$-38.74M | -$-56.06M | -$-47.75M | -$-126.84M | -$-117.07M |
| Total equity | $180M | $137.3M | $126.5M | $211.7M | $208.2M |
| Cash and short-term investments | $187.9M | $148.9M | $123.6M | $213.7M | $207.8M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $8.09M | $13.6M |
| Cost of revenue | $1.64M | $2.46M | $2.58M | $0.00 | $0.00 |
| Gross profit | -$-1.64M | -$-2.46M | -$-2.58M | $8.09M | $13.6M |
| Research and development expenses | $140.3M | $96.4M | $76.6M | $78.4M | $58.7M |
| Selling, general and administrative expenses | $38.9M | $33.3M | $27.8M | $29M | $27.1M |
| Other expenses | -$-1.64M | -$-2.46M | -$-2.58M | $7.18M | $0.00 |
| Operating expenses | $177.6M | $127.3M | $101.7M | $114.6M | $85.9M |
| Cost and expenses | $179.2M | $129.7M | $104.3M | $114.6M | $85.9M |
| Interest income | $9.9M | $9.47M | $7.14M | $2.62M | $60K |
| Interest expense | $0.00 | $340K | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $1.64M | $2.46M | $2.58M | $2.41M | $2.96M |
| Ebitda | -$-172.69M | -$-121.9M | -$-93.43M | -$-96.87M | -$-69.22M |
| Operating income | -$-179.21M | -$-129.73M | -$-104.31M | -$-106.45M | -$-72.25M |
| Total other income/expenses, net | $4.88M | $5.03M | $8.3M | $20.5M | $70K |
| Income before tax | -$-174.32M | -$-124.7M | -$-96.02M | -$-85.98M | -$-72.19M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-174.32M | -$-124.7M | -$-96.02M | -$-85.98M | -$-72.19M |
| Weighted average shares outstanding | $87.5M | $40.8M | $19.9M | $8.51M | $7.12M |
| Weighted average diluted shares outstanding | $87.5M | $40.8M | $19.9M | $8.51M | $7.12M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $187.9M | $148.9M | $123.6M | $213.7M | $207.8M |
| Net receivables | $0.00 | $0.00 | $0.00 | $0.00 | $110K |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $205.5M | $157.3M | $129.7M | $219.6M | $222.6M |
| Property, plant and equipment, net | $26.1M | $29M | $33.2M | $38.6M | $7.6M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $27.1M | $31.4M | $35.2M | $40.6M | $9.77M |
| Total assets | $232.5M | $188.7M | $164.9M | $260.3M | $232.4M |
| Accounts payable | $3.22M | $4.24M | $2.03M | $3.24M | $4.46M |
| Short-term debt | $2.1M | $3.02M | $2.32M | $2.56M | $1.5M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $8.08M |
| Total current liabilities | $33.5M | $30.3M | $14.5M | $22.5M | $23.6M |
| Long-term debt | $19.1M | $21.2M | $23.9M | $26M | $570K |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $19.1M | $21.2M | $23.9M | $26.1M | $570K |
| Capital lease obligations | $21.2M | $24.2M | $26.3M | $28.6M | $2.06M |
| Total liabilities | $52.5M | $51.4M | $38.5M | $48.6M | $24.2M |
| Common stock | $80K | $40K | $20K | $20K | $10K |
| Retained earnings | -$-957.77M | -$-783.45M | -$-658.75M | -$-562.74M | -$-476.76M |
| Accumulated other comprehensive income (loss) | $50K | $50K | $10K | -$-70K | -$-40K |
| Total equity | $180M | $137.3M | $126.5M | $211.7M | $208.2M |
| Total investments | $128M | $68.7M | $49.6M | $58.3M | $88.6M |
| Total debt | $21.2M | $24.2M | $26.3M | $28.6M | $2.06M |
| Net debt | -$-38.74M | -$-56.06M | -$-47.75M | -$-126.84M | -$-117.07M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-174.32M | -$-124.7M | -$-96.02M | -$-85.98M | -$-72.19M |
| Depreciation and amortization | -$-1.87M | $2.46M | $2.58M | $2.41M | $2.96M |
| Stock-based compensation | $16.9M | $10.5M | $7.62M | $7.54M | $13.4M |
| Change in working capital | -$-6.82M | $2.85M | -$-6.34M | -$-3.69M | -$-23.04M |
| Accounts receivable | $0.00 | $0.00 | $0.00 | $110K | -$-110K |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | -$-11.5M |
| Accounts payable | -$-1.09M | $2.21M | -$-760K | -$-5.25M | $1.21M |
| Net cash provided by operating activities | -$-156.29M | -$-100.01M | -$-94.18M | -$-97.98M | -$-77.76M |
| Investments in property, plant and equipment | -$-1.15M | -$-650K | -$-1.51M | -$-3.02M | -$-1.28M |
| Acquisitions, net | $90K | $10K | $0.00 | $31.5M | $89.8M |
| Net cash used for investing activities | -$-58.45M | -$-16.09M | $9.69M | $59.2M | -$-91.09M |
| Common stock issued | $194.7M | $127.2M | $2.97M | $72.6M | $134.9M |
| Common stock repurchased | $0.00 | -$-5.11M | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $194.5M | $122.4M | $3.12M | $74.8M | $135M |
| Net change in cash | -$-20.3M | $6.34M | -$-81.37M | $36M | -$-33.87M |
| Cash at end of period | $61.9M | $82.2M | $74M | $157.2M | $121.2M |
| Operating cash flow | -$-156.29M | -$-100.01M | -$-94.18M | -$-97.98M | -$-77.76M |
| Capital expenditure | -$-1.15M | -$-650K | -$-1.51M | -$-3.02M | -$-1.28M |
| Free cash flow | -$-157.44M | -$-100.67M | -$-95.69M | -$-100.99M | -$-79.05M |
Line items
Line items
Line items
About Solid Biosciences Inc.
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD. Beyond specific drug candidates, Solid Biosciences is actively developing innovative platform technologies, such as "dual gene expression," a technique that allows for multiple therapeutic genes to be bundled into a single viral vector, and researching new capsid designs. The company maintains a strategic alliance through a collaboration and license agreement with Ultragenyx Pharmaceutical Inc., focusing on the joint development and market introduction of novel gene therapies for Duchenne Muscular Dystrophy. Founded in 2013, Solid Biosciences Inc. conducts its operations from its headquarters in Cambridge, Massachusetts.
- CEO
- Alexander G. Cumbo
- Employees
- 121
- Beta
- 2.36
Explore
Frequently asked questions
What is the intrinsic value of Solid Biosciences Inc. (SLDB)?
InvestorsCraft does not currently publish an intrinsic value for SLDB. How the IC value is calculated.
Is SLDB undervalued?
InvestorsCraft does not publish an undervaluation signal for SLDB at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.